Membranoproliferative Glomerulonephritis - A New Look at an Old Entity

New England Journal of Medicine

Volumn 366, Issue 12, 2012, Pages 1119-1131

  Sethi, Sanjeev ^a   Fervenza, Fernando C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5; COMPLEMENT FACTOR; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DIPYRIDAMOLE; ECULIZUMAB; GLUCOCORTICOID; HEPARIN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; WARFARIN;

ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; BINDING AFFINITY; BINDING SITE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPOSITION; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG PULSE THERAPY; ELECTRON MICROSCOPY; GENETIC RISK; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE COMPLEX DEPOSITION; INNATE IMMUNITY; INTERMETHOD COMPARISON; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; MONOCLONAL IMMUNOGLOBULINEMIA; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BINDING; RECURRENT DISEASE; REGULATORY MECHANISM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYNDROME DELINEATION;

EID: 84858668780     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1108178     Document Type: Review

References (100)

1. Swaminathan S, Leung N, Lager DJ, et al. Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30- year renal biopsy study. Clin J Am Soc Nephrol 2006;1:483-7.
2. Briganti EM, Dowling J, Finlay M, et al. The incidence of biopsy-proven glomerulonephritis in Australia. Nephrol Dial Transplant 2001;16:1364-7. (Pubitemid 32640589)
3. Braden GL, Mulhern JG, O'Shea MH, Nash SV, Ucci AA Jr, Germain MJ. Changing incidence of glomerular diseases in adults. Am J Kidney Dis 2000;35:878-83. (Pubitemid 30238200)
4. Zhou FD, Zhao MH, Zou WZ, Liu G, Wang H. The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre. Nephrol Dial Transplant 2009; 24:870-6.
5. Maisonneuve P, Agodoa L, Gellert R, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/ New Zealand: results from an international comparative study. Am J Kidney Dis 2000;35:157-65. (Pubitemid 30027256)
6. Jennette JC, Olson LJ, Schwartz MM, Silva GF, eds. Heptinstall's pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2007.
7. Kumar V, Abul AK, Fausto N, Aster J, eds. Pathologic basis of disease. 8th ed. Philadelphia: Elsevier Saunders, 2010.
8. Rennke HG. Secondary membrano-proliferative glomerulonephritis. Kidney Int 1995;47:643-56.
9. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 2011;31: 341-8.
10. Doutrelepont J-M, Adler M, Willems M, Durez P, Yap S-H. Hepatitis C infection and membranoproliferative glomerulonephritis. Lancet 1993;341:317.
11. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465-70. (Pubitemid 23056436)
12. Roccatello D, Fornasieri A, Giachino O, et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007;49:69-82. (Pubitemid 44932190)
13. Smith KD, Alpers CE. Pathogenic mechanisms in membranoproliferative glomerulonephritis. Curr Opin Nephrol Hypertens 2005;14:396-403. (Pubitemid 40863080)
14. Rincón B, Bernis C, Arcia A, Traver JA. Mesangiocapillary glomerulonephritis associated with hydatid disease. Nephrol Dial Transplant 1993;8:783-4. (Pubitemid 23237677)
15. Martinelli R, Noblat AC, Brito E, Rocha H. Schistosoma mansoni-induced mesangiocapillary glomerulonephritis: influence of therapy. Kidney Int 1989;35:1227-33.
16. Rodrigues VL, Otoni A, Voieta I, Antunes CM, Lambertucci JR. Glomerulonephritis in Schistosomiasis mansoni: a time to reappraise. Rev Soc Bras Med Trop 2010;43:638-42.
17. Ohara S, Kawasaki Y, Takano K, et al. Glomerulonephritis associated with chronic infection from long-term central venous catheterization. Pediatr Nephrol 2006;21:427-9. (Pubitemid 43280363)
18. Vella J, Carmody M, Campbell E, Browne O, Doyle G, Donohoe J. Glomerulonephritis after ventriculo-atrial shunt. QJM 1995;88:911-8. (Pubitemid 26009660)
19. Kai H, Shimizu Y, Hagiwara M, et al. Post-MRSA infection glomerulonephritis with marked Staphylococcus aureus cell envelope antigen deposition in glomeruli. J Nephrol 2006;19:215-9. (Pubitemid 44420115)
20. Ades L, Akposso K, Costa de Beauregard MA, et al. Bacterial endocarditis associated with crescentic glomerulonephritis in a kidney transplant patient: first case report. Transplantation 1998;66:653-4. (Pubitemid 28433851)
21. Pecchini F, Bufano G, Ghiringhelli P. Membranoproliferative glomerulonephritis secondary to tuberculosis. Clin Nephrol 1997;47:63-4.
22. Bonarek H, Bonnet F, Delclaux C, Deminière C, De Précigout V, Aparicio M. Reversal of c-ANCA positive mesangiocapillary glomerulonephritis after removal of an infected cysto-atrial shunt. Nephrol Dial Transplant 1999;14:1771-3. (Pubitemid 29313063)
23. Laso MC, Cadario M, Haymes L, Grimoldi I, Balbarrey Z, Casanueva E. Mycoplasma pneumoniae detection with PCR in renal tissue of a patient with acute glomerulonephritis. Pediatr Nephrol 2006; 21:1483-6. (Pubitemid 44283485)
24. Altiparmak MR, Pamuk G, Pamuk O, Tabak F. Brucella glomerulonephritis: review of the literature and report on the first patient with brucellosis and mesangiocapillary glomerulonephritis. Scand J Infect Dis 2002;34:477-80. (Pubitemid 34826564)
25. Dathan JR, Heyworth MF. Glomerulonephritis associated with Coxiella burnetii endocarditis. BMJ 1975;1:376-7.
26. Jose MD, Bannister KM, Clarkson AR, Whitehead FJ, Faull RJ. Mesangiocapillary glomerulonephritis in a patient with Nocardia pneumonia. Nephrol Dial Transplant 1998;13:2628-9. (Pubitemid 28445882)
27. Elmaci I, Senday D, Silav G, et al. Nocardial cerebral abscess associated with mycetoma, pneumonia, and membrano-proliferative glomerulonephritis. J Clin Microbiol 2007;45:2072-4. (Pubitemid 46933966)
28. Hulton SA, Risdon RA, Dillon MJ. Mesangiocapillary glomerulonephritis associated with meningococcal meningitis, C3 nephritic factor and persistently low complement C3 and C5. Pediatr Nephrol 1992;6:239-43.
29. Boseman P, Lewin M, Dillon J, Sethi S. Marfan syndrome, MPGN, and bacterial endocarditis. Am J Kidney Dis 2008; 51:697-701. (Pubitemid 351400839)
30. Haffner D, Schindera F, Aschoff A, Matthias S, Waldherr R, Schärer K. The clinical spectrum of shunt nephritis. Nephrol Dial Transplant 1997;12:1143-8. (Pubitemid 27230548)
31. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15: 241-50. [Erratum, Am J Soc Nephrol 2004; 15:835-6.] (Pubitemid 38140764)
32. Goules A, Masouridi S, Tzioufas AG, Ioannidis JPA, Skopouli FN, Moutsopoulos HM. Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. Medicine 2000;79: 241-9. (Pubitemid 30616972)
33. Cortez MS, Sturgill BC, Bolton WK. Membranoproliferative glomerulonephritis with primary Sjögren's syndrome. Am J Kidney Dis 1995;25:632-6.
34. Suzuki H, Hickling P, Lyons CB. A case of primary Sjögren's syndrome, complicated by cryoglobulinemic glomerulonephritis, pericardial and pleural effusions. Br J Rheumatol 1996;35:72-5.
35. Ting HC, Wang F. Mesangiocapillary (membranoproliferative) glomerulonephritis and rheumatoid arthritis. BMJ 1977;1: 270-1. (Pubitemid 8021362)
36. Sethi S, Zand L, Leung N, et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 2010;5:770-82.
37. Salant DJ, Sanchorawala V, D'Agati VD. A case of atypical light chain deposition disease - diagnosis and treatment. Clin J Am Soc Nephrol 2007;2:858-67.
38. Vilayur E, Trevillian P, Walsh M. Monoclonal gammopathy and glomerulopathy associated with chronic lymphocytic leukemia. Nat Clin Pract Nephrol 2009;5:54-8.
39. Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 2009;20:2055-64.
40. Smith RJH, Alexander J, Barlow PN, et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007;18:2447-56. (Pubitemid 47378860)
41. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009;9:729-40.
42. Ferreira VP, Pangburn MK, Cortés C. Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol 2010;47:2187-97.
43. Pangburn MK, Müller-Eberhard HJ. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3a. Ann N Y Acad Sci 1983;421:291-8. (Pubitemid 14145056)
44. Zipfel PF, Smith RJH, Skerka C. Factor I and factor H deficiency in renal diseases: similar defects in the fluid phase have a different outcome at the surface of the glomerular basement membrane. Nephrol Dial Transplant 2009;24:385-7.
45. Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005;16: 1392-403. (Pubitemid 41716523)
46. Habbig S, Mihatsch MJ, Heinen S, et al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 2009;75:1230-4.
47. Servais A, Frémeaux-Bacchi V, Lequintrec M, et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007;44:193-9. (Pubitemid 46580528)
48. Gale DP, de Jorge EG, Cook HT, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010;376:794-801.
49. Sethi S, Fervenza FC, Zhang Y, et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 2011;6:1009-17.
50. Józsi M, Zipfel PF. Factor H family proteins and human diseases. Trends Immunol 2008;29:380-7.
51. Athanasiou Y, Voskarides K, Gale DP, et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 2011;6:1436-46.
52. Licht C, Heinen S, Jozsi M, et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 2006;70:42-50. (Pubitemid 44000119)
53. Zhang Y, Meyer NC, Wang K, et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 2012;7:265-74.
54. Martínez-Barricarte R, Heurich M, Valdes-Cañedo F, et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010;120:3702- 12.
55. Strobel S, Zimmering M, Papp K, Prechl J, Józsi M. Anti-factor B autoantibody in dense deposit disease. Mol Immunol 2010;47:1476-83.
56. Abrera-Abeleda MA, Nishimura C, Frees K, et al. Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 2011;22: 1551-9.
57. Heurich M, Martínez-Barricarte R, Francis NJ, et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci U S A 2011;108:8761-6.
58. Abrera-Abeleda MA, Nishimura C, Smith JLH, et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 2006;43:582-9. (Pubitemid 44048765)
59. Lau KK, Smith RJ, Kolbeck PC, Butani L. Dense deposit disease and the factor H H402 allele. Clin Exp Nephrol 2008;12: 228-32.
60. Sethi S, Gamez JD, Vrana JA, et al. Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int 2009;75:952-60.
61. Sethi S, Sukov WR, Zhang Y, et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis 2010;56:977-82.
62. Bridoux F, Desport E, Frémeaux-Bacchi V, et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol 2011;6:2165-74.
63. Servais A, Noël L-H, Dragon-Durey M-A, et al. Heterogeneous pattern of renal disease associated with homozygous Factor H deficiency. Hum Pathol 2011;42: 1305-11.
64. Walker PD, Ferrario F, Joh K, Bonsib SM. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol 2007;20:605-16. (Pubitemid 46788867)
65. Fakhouri F, Frémeaux-Bacchi V, Noël L-H, Cook HT, Pickering MC. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010;6:494-9.
66. Goldberg RJ, Nakagawa T, Johnson RJ, Thurman JM. The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis 2010;56:1168-74.
67. Noris M, Remuzzi G. Atypical hemolytic- uremic syndrome. N Engl J Med 2009;361:1676-87.
68. Pickering M, Cook HT. Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens 2011;20: 271-7.
69. Glassock RJ. Membranoproliferative glomerulonephritis. In: Ponticelli C, Glassock RJ, eds. Treatment of primary glomerulonephritis. 2nd ed. Oxford, England: Oxford University Press, 2009:375-98.
70. Donadio JV Jr, Offord KP. Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis. Am J Kidney Dis 1989;14:445-51. (Pubitemid 20057890)
71. Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatr Nephrol 2010;25:1409-18.
72. McEnery PT, McAdams AJ, West CD. The effect of prednisone in a high-dose, alternate-day regimen on the natural history of idiopathic membranoproliferative glomerulonephritis. Medicine (Baltimore) 1985;64:401-24. (Pubitemid 16197705)
73. McEnery PT. Membranoproliferative glomerulonephritis: the Cincinnati experience - cumulative renal survival from 1957 to 1989. J Pediatr 1990;116:S109-14. (Pubitemid 20162811)
74. Ford DM, Briscoe DM, Shanley PF, Lum GM. Childhood membranoproliferative glomerulonephritis type I: limited steroid therapy. Kidney Int 1992;41:1606-12.
75. Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr. Treatment of mesangiocapillary glomerulonephritis with alternate- day prednisone - a report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1992;6:123-30.
76. Schena FP, Cameron JS. Treatment of proteinuric idiopathic glomerulonephritides in adults: a retrospective survey. Am J Med 1988;85:315-26.
77. Cattran DC, Cardella CJ, Roscoe JM, et al. Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int 1985;27:436-41. (Pubitemid 15142698)
78. Donadio JV Jr, Anderson CF, Mitchell JC III, et al. Membranoproliferative glomerulonephritis: a prospective clinical trial of platelet-inhibitor therapy. N Engl J Med 1984;310:1421-6. (Pubitemid 14101297)
79. Cattran DC. Current status of cyclosporin A in the treatment of membranous, IgA and membranoproliferative glomerulonephritis. Clin Nephrol 1991; 35:Suppl 1:S43-S47.
80. Matsumoto H, Shibasaki T, Ohno I, et al. Effect of cyclosporin monotherapy on proteinuria in a patient with membranoproliferative glomerulonephritis. Nippon Jinzo Gakkai Shi 1995;37:258-62. (In Japanese.)
81. Haddad M, Lau K, Butani L. Remission of membranoproliferative glomerulonephritis type I with the use of tacrolimus. Pediatr Nephrol 2007;22:1787-91. (Pubitemid 47337438)
82. Bagheri N, Nemati E, Rahbar K, Nobakht A, Einollahi B, Taheri S. Cyclosporine in the treatment of membranoproliferative glomerulonephritis. Arch Iran Med 2008;11:26-9. (Pubitemid 351233546)
83. Emre S, Sirin A, Alpay H, et al. Pulse methylprednisolone therapy in children with membranoproliferative glomerulonephritis. Acta Paediatr Jpn 1995;37:626-9.
84. Bahat E, Akkaya BK, Akman S, Karpuzoglu G, Guven AG. Comparison of pulse and oral steroid in childhood membranoproliferative glomerulonephritis. J Nephrol 2007;20:234-45. (Pubitemid 47072408)
85. Bergstein JM, Andreoli SP. Response of type I membranoproliferative glomerulonephritis to pulse methylprednisolone and alternate-day prednisone therapy. Pediatr Nephrol 1995;9:268-71.
86. Chapman SJ, Cameron JS, Chantler C, Turner D. Treatment of mesangiocapillary glomerulonephritis in children with combined immunosuppression and anticoagulation. Arch Dis Child 1980;55:446-51. (Pubitemid 10056180)
87. Faedda R, Satta A, Tanda F, Pirisi M, Bartoli E. Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron 1994;67:59-65. (Pubitemid 24119471)
88. Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002;61:1098-114. (Pubitemid 34175479)
89. Bayazit AK, Noyan A, Cengiz N, Anarat A. Mycophenolate mofetil in children with multidrug-resistant nephrotic syndrome. Clin Nephrol 2004;61:25-9. (Pubitemid 38100840)
90. Jones G, Juszczak M, Kingdon E, Harber M, Sweny P, Burns A. Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant 2004;19:3160-4. (Pubitemid 40057644)
91. Guiard E, Karras A, Plaisier E, et al. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol 2011;6:1609-16.
92. Cameron JS, Turner DR, Heaton J, et al. Idiopathic mesangiocapillary glomerulonephritis: comparison of types I and II in children and adults and long-term prognosis. Am J Med 1983;74:175-92. (Pubitemid 13192172)
93. D'Amico G, Ferrario F. Mesangiocapillary glomerulonephritis. J Am Soc Nephrol 1992;2:Suppl:S159-S166.
94. Nester C, Stewart Z, Myers D, et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011;6:1488-94.
95. Lapeyraque A-L, Frémeaux-Bacchi V, Robitaille P. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 2011;26:621-4.
96. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009;360:544-6.
97. Licht C, Weyersberg A, Heinen S, et al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005;45:415- 21.
98. Andresdottir MB, Assmann KJM, Hoitsma AJ, Koene RAP, Wetzels JFM. Recurrence of type I membranoproliferative glomerulonephritis after renal transplantation: analysis of the incidence, risk factors, and impact on graft survival. Transplantation 1997;63:1628-33. (Pubitemid 27265506)
99. Karakayali FY, Ozdemir H, Kivrakdal S, Colak T, Emiroǧlu R, Haberal M. Recurrent glomerular diseases after renal transplantation. Transplant Proc 2006;38: 470-2.
100. Lorenz EC, Sethi S, Leung N, Dispenzieri A, Fervenza FC, Cosio FG. Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int 2010;77:721-8.